Dna X (SONM) Liabilities and Shareholders Equity (2018 - 2025)
Dna X filings provide 8 years of Liabilities and Shareholders Equity readings, the most recent being $43.9 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 10.47% to $43.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $156.2 million, a 11.85% decrease, with the full-year FY2025 number at $43.9 million, up 10.47% from a year prior.
- Liabilities and Shareholders Equity hit $43.9 million in Q4 2025 for Dna X, up from $40.2 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $58.6 million in Q3 2023 to a low of $36.0 million in Q1 2025.
- Median Liabilities and Shareholders Equity over the past 5 years was $41.7 million (2021), compared with a mean of $44.5 million.
- Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 42.8% in 2021 and later skyrocketed 44.11% in 2023.
- Dna X's Liabilities and Shareholders Equity stood at $41.1 million in 2021, then soared by 30.65% to $53.7 million in 2022, then increased by 4.39% to $56.0 million in 2023, then decreased by 29.09% to $39.7 million in 2024, then increased by 10.47% to $43.9 million in 2025.
- The last three reported values for Liabilities and Shareholders Equity were $43.9 million (Q4 2025), $40.2 million (Q3 2025), and $36.1 million (Q2 2025) per Business Quant data.